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Abstract Headache and facial pain are among the most
common, disabling and costly disorders in Europe. Correct
diagnosis and treatment is important for achieving a high
quality of care. As a national organisation whose role is to
educate and advocate for the needs of patients with primary
headaches, the Danish Headache Society has set up a task
force to develop a set of guidelines for the diagnosis,
organisation and treatment of the most common types of
headaches and for trigeminal neuralgia in Denmark. The
guideline was published in Danish in 2010 and has been a
great success. The Danish Headache Society decided to
translate and publish our guideline in English to stimulate
the discussion on optimal organisation and treatment of
headache disorders and to encourage other national head-
ache authorities to produce their own guidelines. The rec-
ommendations regarding the most common primary
headaches and trigeminal neuralgia are largely in accor-
dance with the European guidelines produced by the Euro-
pean Federation of Neurological Societies. The guideline
provides a practical tool for use in daily clinical practice for
primary care physicians, neurologists with a common
interest in headache, as well as other health-care profes-
sionals treating headache patients. The guideline ﬁrst
describeshowtoexamineanddiagnosetheheadachepatient
and how headache treatment is organised in Denmark. This
description is followed by individual sections on the char-
acteristics, diagnosis, differential diagnosis and treatment of
each of the major headache disorders and trigeminal neu-
ralgia. The guideline includes many tables to facilitate a
quick overview. Finally, the particular problems regarding
headache in children and headache in relation to female
hormones and pregnancy are described.
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1 Introduction
Headache conditions are among the ten most costly dis-
eases in Europe and one in every three Danes have seen a
physician at some point in their lives due to a headache. In
a normal Danish general practice, more than 10% of
patients have migraine and more than 5% suffer from a
chronic, often incapacitating, headache. Due to the high
occurrence, the overall socioeconomic costs derived from
headaches are substantial and also cause 20% of the overall
sickness absence recorded in the total Danish workforce.
The quality of life of patients who suffer from headaches is
also considerably reduced. Consumption of medication
follows an increasing trend and the recent introduction of
novel speciﬁc migraine medications and novel prophylactic
pharmaceuticals contributes to a considerable need to
establish a systematic and updated treatment strategy in
Denmark. The overwhelming majority of Danes who suffer
from headaches are currently being treated in primary
health care and should continue to be so in future, but there
is a growing need for clear guidelines on referral and
organisation of specialist treatment of the more severe and
rare headache conditions.
International general recommendations on the treatment
of migraine and other primary headache disorders are now
in place, and there is a substantial need to implement such
guidelines in the Danish context.
In Denmark, patients with trigeminal neuralgia and other
types of facial pain are typically treated by specialised neu-
rologists, but even in this ﬁeld there is a growing need for
organisation and systematisation of treatment offers, par-
ticularly in the light of novel treatment strategies. This type
of neuralgia is closely related to headache conditions and is
therefore included in the present guidelines.
On this background, the Danish Headache Society
established a workgroup with a view to revising the pre-
vious Danish reference programme on headache conditions
from 1994. The present reference programme was prepared
in relation to the general recommendations made by the
previous Reference Programme Committee of the Danish
NationalBoardofHealthandhasbeenthesubjectofahearing
phase in the Danish Neurological Society and Danish Head-
acheSociety.Inthepresentpaper,thereferenceprogrammeis
translated into English and adapted to journal format. The
original reference programme in colour can be downloaded
for free at http://www.dhos.dk/index15.htm.
1.1 Objective
The objective of this programme is to establish guidelines
for the:
• diagnosis,
• organisation and
• treatment of the most frequently occurring primary head-
ache disorders in Denmark such as migraine, tension-type
headache,clusterheadacheandtrigeminalneuralgiaandto
• describe the ‘‘warning signs’’ of serious life-threatening
and other secondary headache conditions.
1.2 Introduction to the guidelines
Thecurrentguidelinesincludetablestoincreaseusabilityand
facilitate quick lookups in the context of a clinical working
day. Consequently, the sections may be read separately and
the primary points are repeated. The tables include ICD-10
and ICPC-2 diagnostic codes, e.g. Table 3 [G43.0/N89].
Following an introductory section with background and
general information and a summary, focus is on the diag-
nostic process and on clinical investigation and organisa-
tion. In headache disorders and facial pain, the medical
history is essential as the diagnosis is based on the history
in the overwhelming majority of cases. A correct diagnosis
is an essential prerequisite to correct treatment.
Next, the individual headache disorders are described in
separate sections including characteristics, diagnosis, dif-
ferential diagnoses, treatment and a list of references.
Finally, we describe the speciﬁc problems related to chil-
dren and adolescents and to women in relation to hor-
mones, pregnancy and lactation.
A joint and comprehensive evidence assessment of the
recommended treatments exists, but herein we have chosen
not to state the evidence class to improve readability and
reduce the amount of text. For further information, please
refer to the recommended literature.
1.3 Target audience
Any physician or other health-care professional who regu-
larly sees patients with headaches and facial pain, primarily
general practitioners (GP), junior physicians in training,
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123neurologists and paediatricians working in practices and at
hospitals and, ﬁnally, public sector decision-makers.
2 Diagnosis and organisation
2.1 Occurrence
Most of us have a headache occasionally and consider this a
normal, temporary phenomenon. Headache is, however, a
problem for approximately 40% of the European population.
An average general practice (1,500 patients) comprises:
• 150 adults and 30 children with bothersome migraine;
• 65 adults and 10 children with daily headaches, a consid-
erable share of whom have medication overuse headaches;
• 1 patient with cluster headache.
Table 1 summarises the primary types of headache and
facial pain.
2.2 Taking a medical history on headache/facial pain
Themedicalhistoryiscrucialtothediagnosticsinallprimary
headache conditions, facial neuralgias and medication over-
use headaches (Table 2). No reliable, diagnostic tests exist.
Themedical historyshall reveal any warningsigns indicating
the presence of a serious secondary headache.
Table 2
Useful questions
How many different types of headache/facial pain do you experience?
Take a separate history for each type!
Developments over time Why have you chosen to see a physician
now?
When did the pain start?
How often do you experience the pain
(episodically, daily and/or constantly)?
How long does each attack last?
Character Intensity of the pain experienced?
Quality and type of pain?
Where is the pain located and is it
spreading?
Accompanying symptoms?
Causes Predisposing and/or trigger factors?
Aggravating and alleviating factors?
Familiar disposition for headache/facial
pain?
Pattern of reaction What do you do during an attack?
How is your level of activity affected?
Medication, which and how much?
General state of health
between attacks
Full recovery or any symptoms between
attacks?
Preoccupation, anxiety or fear of new
attacks and their causes?
Table 1
Any patient may have several
types of headache and facial
pain concurrently and a
considerable number of
headache conditions are
secondary to other conditions.
Some of these are serious and
should be identiﬁed (see
Sect. 7), but in general these
conditions are relatively rare
and comprise\1% of the
patients seen with a headache in
primary health care
Character Possible diagnosis Description Sections
Acutely
occurring
headache
Subarachnoid haemorrhage
among others
Hyperacute, severe headache
± neurological symptoms
7
Episodic
headache
Tension-type headache Pressing headache with no accompanying
symptoms
4
Migraine ± aura Pulsating headache, physical activity
associated with aggravation of the
condition. Accompanied by nausea,
photo- and phonophobia
3
Cluster headache and others Unilateral headache with ipsilateral
autonomic facial symptoms
5
Trigeminal neuralgia Unilateral, stabbing pain lasting a few
seconds
8
Chronic
headache
Medication overuse headache Use of headache medication for more
than 10–15 days/month
6
Chronic tension-type headache Pressing headache with no accompanying
symptoms or medication overuse
4
Increased intracranial pressure
including cerebral tumours
Frequently with increasing intensity,
frequently with nausea and neurological
symptoms
7
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123Warning signals identiﬁed from the history or the physical
examination which warrant further examination are:
• thunderclap headache (severe headache with sudden
onset);
• headache with atypical aura (lasting more than 1 h or
including motor symptoms);
• newly presenting headache in an HIV or cancer patient;
• headache/facial pain accompanied by fever or neuro-
logical symptoms;
• progressive headache lasting weeks;
• newly presenting headache in patients below the age of
10 years or above 40 years.
2.3 Physical examination of a headache/facial pain
patient
Physical and neurological examinations should be performed
to exclude or conﬁrm any secondary headache. The physical
examinationwillgenerallyproducenormalﬁndingsincaseof
aprimaryheadache.Attacks ofclusterheadachewillproduce
physicalﬁndingsincludinglacrimation,reddeningoftheeyes,
ptosis and similar symptoms (see Sect. 5). In trigeminal
neuralgia, pain trigger points can often be identiﬁed (see
Sect. 8). Blood pressure and pulse should always be taken.
CT/MRI scans are rarely indicated, but should be performed
wherethehistoryorphysicalexaminationraisesuspicionofa
secondary condition.
2.4 Diagnostic diary and calendar
Once a serious secondary headache has been excluded, the
use of a headache diary (Fig. 1) for a minimum of 4 weeks
and a headache calendar (Fig. 2) for a few months is highly
recommendable.
Headache diaries and calendars may be downloaded
and/or ordered at the Danish Headache Society’s Web page
http://www.dhos.dk. These tools reveal to the physician
and patient the headache pattern and also assist in identi-
fying any trigger factors and medication overuse.
2.5 Organisation of treatment in Denmark
Diagnosis and treatment are generally performed at
three levels (see Fig. 3). European guidelines have now
been published on the organisation of headache conditions.
In Denmark, diagnosis and treatment of headaches is and
should generally be performed in primary health care, i.e.
with the GP as the key health-care professional.
At the second level, diagnosis and treatment are per-
formed by practising specialists of neurology or other
related health-care staff with an interest/experience in pain
conditions or by local neurology departments.
The tertiary level comprises headache centres, where med-
ical specialists and cross-disciplinary staff specialised in head-
ache conditions are responsible for diagnosis and treatment.
ThislevelisthehighestlevelavailableinDenmark(seeFig. 3).
3 Migraine with and without aura
3.1 Diagnosis
The two most frequently occurring types of migraine are
migraine with aura and migraine without aura. Many
patients have both types. Migraine without aura presents as
attacks lasting from 4 to 72 h and the typical characteristics
are throbbing unilateral headaches of moderate to severe
intensity with aggravation by routine physical activity.
These headaches are typically accompanied by nausea,
vomiting and phono- and photophobia (see Table 3).
Patients are symptom-free between attacks. The interna-
tional headache classiﬁcation [1] marked a substantial step
forward for our understanding of the various types of head-
ache, but also has the weakness of focusing on symptoms
ratherthan patients. Itmay thereforebe usefulto focus on the
overall differences between migraine and the most frequent
differential diagnosis, tension-type headache, when the
diagnosisismade.Furthermore,itisimportanttokeepinmind
that many patients suffer from migraine as well as tension-
typeheadache.Table 4summarisesthetypicalcharacteristics
of the two types of headache.
Approximately, a third of migraine patients have
migraine with aura [2]. The aura phase consists of latera-
lised, reversible symptoms from the vision and tactile sen-
ses, such as ﬂickering scotoma and sensory disturbances.
Transitory aphasia also occurs. Typically, symptoms
develop gradually over minutes, every aura symptom has a
duration of 5–60 min and several types of symptoms follow
in a sequence (see Table 3). If aura includes motor weak-
ness, the condition is classiﬁed as hemiplegic migraine. In
migraine with aura, the headache phase frequently meets
the criteria for migraine without aura and is then classiﬁed
as typical aura with migraine headache (see Table 3). It
should be noted that aura is not necessarily followed by
headache, and that such headache does not necessarily meet
the criteria for migraine without aura. In these cases, the
migraine is diagnosed as typical aura with non-migraine
headache or as typical aura with no headache [1].
3.2 Background
Migraine conditions occur very frequently in Denmark
with a lifetime prevalence of 16% [3, 4]. Migraine occurs
in all age groups, also in children (see Sect. 10). More
women than men have migraine. This is a particularly
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123DIAGNOSTIC HEADACHE DIARY
Complete the diary every evening. Tick the boxes that fit the questions best. Read the instructions carefully.
Name: _______________________________________ Birth Date: ____________________
From date:  - 20  to date:  - 20
1. Year: Date: M     / T     / W/ T     / F     / S/ S     /
2. Did you have a headache today                    no:
yes:
When did the headache begin?                      hour:
3. When did the headache disappear? hour:
4. Just before the headache visual disturbance:
began, was there any sensory disturbance:
difficulty speaking:
5. Was the headache on both sides:
right sided:
left sided:
6. Was the headache  pressing/tightening:
pulsating/throbbing:
7. Was the headache mild:
- on average moderate: 
(see * below) severe:
8. Was the headache aggravated by no:
physical activity, e.g. walking on stairs? yes:
9. Did you suffer from nausea? no:
mild:
moderate:
severe:
10. Were you bothered by light? no:
yes:
11. Were you bothered by sounds? no:
yes:
12. Did anything trigger  if yes, please specify:
this headache attack
13. Did you take any medicine for 
headache or for any other pain?
(for each, please write name, 
amount and the time you took it)
name:
amount:
time:
name:
amount:
time:
name:
amount:
time:
*) Mild = does not inhibit work or other activities.
Moderate = inhibits, but does not prohibit work or other activities.
Severe= prohibits work or other activities.
Fig. 1 Headache diary. Available for download at http://www.dhos.dk
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123Birth date: Name: Year: 20
Jan
h.ache/medicine
Feb
h.ache/medicine
March
h.ache/medicine
April
h.ache/medicine
May
h.ache/medicine
June
h.ache/medicine
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
July
h.ache/medicine
August  
h.ache/medicine
September   
h.ache/medicine
October  
h.ache/medicine
November  
h.ache/medicine
December
h.ache/medicine
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
Headache Calendar
Instructions:
Complete the calendar every evening.
Write severity of headache to the left and intake 
of medicine for headache or other pain to the right.
Indicate severity of the pain as an average of the day:
Migraine: 
1 = mild;    2 = moderate; 3 = severe
Tension-type headache: 
x = mild;    xx = moderate;    xxx = severe
Cluster headache (Horton):
z = mild;    zz = moderate; zzz = severe
Trigeminal neuralgia:
o = mild;    oo = moderate;   ooo = severe
Mild: 
Does not inhibit work or other activities.
Moderate: 
Inhibits, but does not prohibit work or other activities.
Severe: 
Prohibts work and other activities.
Note number of tablets and symbol for the pills, e.g. 2 paracetamol as 2P.
Bring this headache calendar at all visits to the Danish Headache Center.
Notes: 
Danish Headache Center
Glostrup University Hospital
DK-2600 Glostrup
Tel:   3863 2062
Fax: 3863 3839
hovedpineafbud@regionh.dk
Physician: 
Fig. 2 Headache calendar. Available for download at http://www.dhos.dk. Fold around the centre to A5 format; however, it may also be folded
twice to A6 format to ﬁt a pocket book or similar such book
Fig. 3 Organisation of the
diagnosis and treatment of
headache disorders and facial
pain in Denmark
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123pronounced trend in migraine without aura, where the
M/F ratio is 1:3 [3] (see Sect. 9).
Recent times have brought considerable improvements
in our understanding of the mechanisms behind migraine. It
is probable that migraine is a neurovascular disease in
which a genetic disposition makes the brain of patients
susceptible to a series of endogenous and exogenous trigger
factors.
Migraine aura is probably caused by a transitory and
slowly extending reduced neuronal metabolism, which
typically starts occipitally, so-called cortical spreading
depression [5, 6]. Migraine headache is probably caused by
activation of nociceptors in the meninges and cerebral
vessels and by secondary, increased pain sensitivity in the
central nervous system [7].
3.3 Clinical assessment and special assessment
programme
Use of a headache diary is essential to reach the correct
diagnosis, particularly to distinguish between mild
migraine attacks and tension-type headache, and to exclude
medication overuse headache.
Comorbidity, e.g. hypertension, asthma, severe obesity
and depression, shall also be diagnosed and managed.
Comorbid conditions are essential for the choice of pro-
phylactic medication. Migraine is a benign condition, but
women who have migraine with aura are at increased risk of
stroke, even though their absolute risk is small (see Sect. 9).
Typically, there is no need for paraclinical tests; see Sect. 2.
3.4 Non-pharmacological treatment
• Generally, there is only limited evidence to support the
effect of non-pharmacological treatment on migraine.
• In some patients, the following factors have a positive
effect: information about the causes of migraine and
about treatment options; a thorough examination
allowing the patient to feel that he or she is safe and
does not need to fear life-threatening disease; making
the patient feel that he or she is being taken seriously.
• Identify and reduce, to the extent possible, any predis-
posing factors such as stress and depression/anxiety.
• Identify and eliminate, to the extent possible, any
trigger factors, e.g. irregular lifestyle (e.g. poor sleep
pattern or irregular food intake) and consumption of
triggering foods such as red wine and some cheeses.
Table 3 Classiﬁcation of migraine without aura and typical aura with
migraine headache [1]
1.1 [G43.0/N89] Migraine without aura
A. At least ﬁve attacks fulﬁlling criteria B–D
B. Headache attacks lasting 4–72 h (untreated or treated
unsuccessfully)
C. Headache has at least two of the following characteristics:
1. Unilateral localisation
2. Pulsating quality
3. Moderate or severe pain intensity
4. Aggravation by or causing avoidance of routine physical
activity such as climbing stairs
D. During headache at least one of the following:
1. Nausea and/or vomiting
2. Phono- and photophobia
E. Not attributed to another disorder
1.2.1 [G43.10/N89] Typical aura with migraine headache
A. At least two attacks fulﬁlling criteria B–D
B. Aura consisting of at least one of the following, but no motor
weakness:
1. Fully reversible visual symptoms including positive features
(e.g. ﬂickering, spots or lines) and/or negative properties (i.e.
loss of vision)
2. Fully reversible sensory symptoms including positive
features (e.g. pins and needles) and/or negative features (e.g.
numbness)
3. Fully reversible dysphasic speech disturbance
C. At least two of the following:
1. Homonymous visual symptoms and/or unilateral sensory
symptoms
2. At least one aura symptom develops gradually over C5 min
and/or different aura symptoms occur in succession over a period
of C5 min
3. Each symptom lasts C5 and B60 min
D. Headache fulﬁlling criteria B–D 1.1 Migraine without aura
begins during the aura or follows aura within 60 min
E. Not attributed to another disorder
Table 4 Characteristics to distinguish between migraine and tension-type headache
Migraine Tension-type headache
Time pattern Attacks lasting 4–72 h Varies, from episodes lasting 30 min to a
continuous headache
Headache
characteristics
Frequently unilateral and pulsating.
Aggravation by physical activity
Frequently bilateral and pressing. Normally no
aggravation by physical activity
Intensity Typically moderate to severe Typically mild to moderate
Accompanying symptoms Frequent nausea and/or vomiting,
photophobia and phonophobia
None or only a mild nausea, photophobia or phonophobia
J Headache Pain (2012) 13 (Suppl 1):S1–S29 S7
123• Physiotherapy should primarily comprise instruction on
how to maintain a correct work posture, correcting
posture in general and instruction allowing the patient
to perform active exercises at home. Physical activity
may be beneﬁcial.
• Biofeedback therapy has a documented effect on
migraine [8].
• Behavioural therapy and cognitive therapy (stress and
pain management) are probably effective, but offered
only to a limited extent in Denmark.
• Controlled trials of the effect of acupuncture have
yielded diverging results.
3.5 Pharmacological treatment
Medical treatment is divided into acute treatment and
prophylactic treatment.
3.5.1 Acute treatment
3.5.1.1 General guidelines
• No certain difference has been demonstrated between
simple analgesics (paracetamol, NSAID and acetylsal-
icylicacid)aloneorincombinationwithantiemeticsand
triptans [9]. Simple analgesics, i.e. in combination with
antiemetics, are therefore ﬁrst-line treatment [10]. Many
of the patients who experience an insufﬁcient effect of
simple analgesics have good effect from triptans [10].
• Step-wise treatment is recommended in which each
step comprises three treatments before progressing to
the next step. Hereby, the most effective and inexpen-
sive treatment is achieved [2, 10].
• The ﬁrst step consists of simple analgesics and an
antiemetic, if needed.
• The second step consists of triptans.
• Ergot alkaloids (ergotamine derivatives) are nearly
obsolete due to the risk of serious side effects. These
should only be used by specialists.
• Treatment should be initiated as early as possible
during the attack [11]; triptans, however, should not be
initiated until after any aura phase.
• Pharmaceutical treatment often has a better effect when
combined with rest and/or sleep. If the patient has
difﬁculty relaxing, benzodiazepine may be given, e.g.
5 mg diazepam.
• Please also refer to the section on prevention of
medication overuse headache (see Sect. 6).
3.5.1.2 Simple analgesics and antiemetics
• It has been demonstrated that the following have an
effect on migraine attacks: paracetamol, acetylsalicylic
acid and various NSAIDs [2, 10]. See Table 5 for
recommended doses.
• In case of accompanying nausea, simple analgesics may
be given in conjunction with antiemetics to manage the
vegetative symptoms and to increase resorption of the
analgesics [12]. The following may be used: metoclo-
pramide 20 mg suppository (or tablet 10–20 mg in case
of aversion against suppositories) or tablet domperi-
done 10–20 mg (this last drug is frequently used in
younger patients owing to its low risk of extrapyrami-
dal side effects); see Table 5.
• Use of simple analgesics should not exceed 14 days/
month to avoid medication overuse headache.
3.5.1.3 Triptans
• Triptans are generally alike with regard to effect and
side effects [13], but the response of each patient to the
various triptans may vary considerably [10]. Table 6
presents the triptans marketed in Denmark.
• Patients who have no effect from one triptan may enjoy
effect from another. To exclude any effect of triptans,
the patient should, as a rule of thumb, have tried three
different triptans, each during three attacks [2].
• Price differences between triptans are considerable.
• There is no evidence that the effect of orally disinte-
grating tablets or rapidly soluble tablets is any quicker
than that of standard tablets. Nasal spray and subcuta-
neous injection act more rapidly than tablets.
• Triptans should be taken early in the attack (while the
pain is mild) [14], but not during the aura phase, as
they are ineffective in this phase [11]. To avoid
overuse of triptans, it is essential that the patient is
able to distinguish between migraine and tension-type
headache.
• Some studies seem to indicate that a combination of a
triptan and an NSAID is superior to each of the
pharmaceuticals alone [15].
Table 5 Acute migraine treatment, ﬁrst step: simple analgesics and
antiemetics with demonstrated effect in migraine attack treatment
using the recommended initial doses [2, 10]
Analgesics Initial
dose (mg)
Antiemetic Initial dose
(mg)
Acetylsalicylic acid 1,000 Metoclopramide 10–20
Ibuprofen 400–600 Domperidone 20
Naproxen 500–750
Diclofenac 50–100
Tolfenamic acid 200
Paracetamol 1,000
These medications can typically be taken two to three times a day
S8 J Headache Pain (2012) 13 (Suppl 1):S1–S29
123• Oral triptans may, in case of severe nausea/vomiting, be
combined with the antiemetic metoclopramide [16]o r
domperidone; in some cases, non-oral administration is
advantageous (nasal spray, suppository or subcutaneous
injection).
• Approximately, 20–50% of patients experience
migraine relapse within 48 h. An additional dose of
triptan is normally effective in these cases. Migraine
relapse may also be managed with NSAID.
• In case of lack of effect from triptans, repetition of the
triptan treatment during the same attack is usually
ineffective.
• Use of triptans should not exceed 9 days/month to
avoid medication overuse headache.
• Common side effects include a sensation of pressure on
the chest, nausea, distal paraesthesia and fatigue.
• Triptans are, among others, contraindicated in cases with
uncontrolled hypertension, ischaemic heart conditions,
previous cerebral infarctions and peripheral vascular
diseases. Caution should be exercised when treating
patients \18 and [65 years. However, sumatriptan
nasal spray 10 mg is approved for use in adolescents
aged 12–17 years. See http://www.medicin.dk for a
comprehensive list.
3.5.2 Prophylactic treatment
3.5.2.1 General guidelines
• Prophylactic treatment is offered to reduce the fre-
quency or severity of attacks.
• Prophylactic treatment should be considered [10]i f
– the number of attacks per month exceeds two;
– attack medications have poor effect;
– the patient’s quality of life is reduced considerably
due to the migraine;
– frequent or very long-lasting cases of aura occur.
• Thorough information to patients on the objective, any
side effects and creation of realistic expectations about
treatment effect is important.
• Prophylactic treatment is generally considered success-
ful if the frequency or intensity of migraine is halved
without introducing bothersome side effects [10].
• Medication overuse shall be managed before treatment
is initiated (see Sect. 6)
• Prophylactic medication shall be chosen on the basis of
the available scientiﬁc evidence for effect, adverse
event proﬁle and competing conditions. Tables 7 and 8
summarise the ﬁrst-, second- and third-line drugs.
• Slow up-titration shall be used to minimise any side
effects.
• A headache calendar shall be used to document any
effect.
• Prophylactic treatment should be attempted for a
minimum of 2–3 months at full dose, before it may
ﬁnally be assessed if it has any effect (unless treatment
is not tolerated due to side effects).
• In case of effect, discontinuation should be attempted
every 6–12 months to conﬁrm that the patient still needs
the medication and that the medication remains effective.
• Lacking effect from one type of prophylaxis does not
preclude the effect of other types of prophylaxis.
Table 6 Acute migraine treatment, second step: triptans available in
Denmark (stated by date of marketing)
Triptan Formulation Comments
Sumatriptan Tablets 50 and 100 mg
Nasal spray 10 and 20 mg
Suppositories 25 mg
Subcutaneous injection 6 mg
Zolmitriptan Tablets 2.5 and 5 mg
Naratriptan Tablets 2.5 mg Less effective than
sumatriptan
Rizatriptan Tablets 10 mg 5 mg when used in
conjunction with
propranolol
treatment
Almotriptan Tablets 12.5 mg Possibly less side
effects than
sumatriptan
Eletriptan Tablets 40 80 mg allowed if
40 mg is ineffective
Frovatriptan Tablets 2.5 mg Possibly less effective,
fewer side effects
and a longer
duration of effect
than sumatriptan
An additional dose may be administered after a minimum of 2 h if the
ﬁrst dose has an effect and the headache returns. Generally, a maxi-
mum of two doses per day
Table 7 Prophylactic migraine medication ﬁrst-line medication [10]
Medicinal product Daily dose
Beta-blockers
Metoprolol 50–200 mg
Propranolol 40–240 mg
Anti-epileptic drugs
Topiramate 25–100 (200) mg
Valproate 500–1,800 mg
Calcium canal blocker
Flunarizine 5–10 mg
Recommended doses
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123• There is no evidence to support an effect from a
combination of several forms of prophylaxis.
• By C4 attacks per month or B10 days with headache
per month, medication overuse should be excluded.
3.5.2.2 Beta-blockers Beta-blockers with no autostimu-
lating effect have a well-documented effect on migraine.
Beta-blockers should normally be selected as the ﬁrst
among ﬁrst-line drugs. Evidence is strongest for propran-
olol and metoprolol [17]. The typical dosage for metoprolol
is 50 mg 91 for a week and then 100 mg 91, increased to
150–200 mg a day in case of lack of effect. The typical
dosage of propranolol is 40 mg 92, increased at a weekly
interval to a maximum of 120 mg 92.
Frequently, an effect is achieved at 120–160 mg daily.
Once the dosage is established, a retard drug may be
introduced to increase compliance. Furthermore, there is
some evidence to support an effect of bisoprolol, timolol
and atenolol [10]. Side effects include fatigue, dizziness,
reduced physical capacity and cool extremities; see Table 7.
3.5.2.3 Anti-epileptic drugs Topiramate [18] and val-
proate have a well-documented effect comparable to that of
beta-blockers, but are generally associated with more side
effects. The typical dosage for topiramate is 25 mg 91,
increased by 25 mg at 14-day intervals to 100 mg/day
divided into two doses and, subsequently, dose adjustment
if needed to 50–200 mg divided into two doses. Side
effects include paraesthesias, sedation, dizziness, weight
loss, kidney stones and a range of cognitive side effects.
The typical dosage of valproate is 1,000 mg 91 and in
some cases a subsequent dose adjustment to 500–1,800 mg
91[ 10]. Side effects include dyspepsia, hand tremors,
weight increase, affection of the liver, thrombocytopaenia
and foetal malformations; see Table 7.
3.5.2.4 Calcium canal blocker The effect of ﬂunarizine
is comparable to that of beta-blockers, but ﬂunarizine is
generally associated with more side effects [20]. The nor-
mal dosage is 10 mg 91, but elderly patients should only
receive half the dose [10]. Side effects include drowsiness,
fatigue, weight increase, depression and unmasking of
latent Parkinson disease; see Table 7.
3.5.2.5 Second- and third-line drugs A range of phar-
maceuticals are available, for which the evidence to sup-
port an effect is weaker or which have more side effects
than the mentioned ﬁrst-line medications. These pharma-
ceuticals are therefore categorised as second or third line;
see Table 8. Several of these will normally only be used by
specialists.
Naproxen dosage is 500 mg 92 and this medication
may also be used in short periods for treatment of men-
strual migraine [21] (see the section on migraine and hor-
mones). Candesartan has few side effects [22]. The typical
dosage for candesartan is 8 mg 91 for a week and then
16 mg 91, if necessary increasing to 24–32 mg a day.
Amitriptyline is particularly suitable if the patient also
suffers from frequent tension-type headaches [10]. The
typical dosage is 10 mg 91 increased by 10 mg at 1-week
intervals to 10–100 mg daily. The entire dose is given
1–2 h before bedtime. The typical dose needed to ensure an
optimal balance between effect and side effects is
30–50 mg daily. Pizotifen should be given as 0.5-mg doses
every third day to 1.5 mg nocte, possibly increasing to
1m g93. Side effects include weight increase and fatigue.
4 Tension-type headache
4.1 Diagnosis
Tension-type headache is characterised by a bilateral,
pressing pain of mild to moderate intensity. Such headache
is not associated with the typical migraine characteristics
such as aggravation by physical activity, vomiting or
severe nausea and sensitivity to light and sound. There
are three main types: (1) sporadic episodic tension-type
headache, (2) frequent episodic tension-type headache and
(3) chronic tension-type headache. The diagnostic criteria
for tension-type headache are shown in Table 9.
4.2 Background
Episodic tension-type headache which occurs no more than
a few times a month rarely causes concern and is often the
Table 8 Prophylactic migraine medication, second- and third-line
medications [10] and recommended doses
Medicinal product Daily dose
Second-line
Amitriptyline 10–100 mg
Naproxen 500 mg 92
Bisoprolol 5–10 mg
Third-line
Candesartan 16 mg
Lisinopril 20 mg
Acetylsalicylic acid 300 mg
Magnesium 360 mg
Riboﬂavine 400 mg
Methysergide 4–12 mg
Gabapentin 1,200–1,600 mg
Pitzotifen 1.5–3 mg
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123body’s warning signal following inexpedient strain, e.g.
due to stress or unphysiological work postures. Frequent
episodic and chronic tension-type headache may, by con-
trast, be very bothersome and may reduce quality of life
considerably [23].
The mechanisms behind tension-type headache are not
fully known, but in the episodic form, referred pain from the
pericranial musculoskeletal tissues and stress probably play
an important role. In patients with frequent and chronic
tension-type headache, it was demonstrated that the central
nervous system was hypersensitive to pain. This may be due
to insufﬁcient inhibition of incoming painful stimuli or a
consequence of frequent painful input from the pericranial
musculoskeletal tissue (central sensitisation) [24].
4.3 Clinical assessment and special assessment
programme
Use of a headache diary is essential to reach the correct
diagnosis, particularly to distinguish between tension-type
headache and mild migraine attacks and to exclude medi-
cation overuse headache.
Physical examination is important, partly to demonstrate
that complaints are taken seriously, and partly to ensure the
exclusion of more serious conditions. Such reassurance
may have an independent beneﬁcial effect, e.g. in patients
who have been worried that they may have a brain tumour.
The examination should include palpation of the pericra-
nial musculature to identify any soreness to assess the
degree of musculoskeletal tensions, the chewing apparatus
for bite dysfunction and sinuses for sinusitis. Comorbid
conditions, particularly depression, should also be diag-
nosed and managed. Many patients would like to have a
neck X-ray performed, but imaging of the neck is only
rarely indicated and only on speciﬁc suspicion of cervical
pathology. For further information on the need for para-
clinical tests, please refer to Sect. 2.
4.4 Non-pharmacological treatment (see Table 10)
Treatment of tension-type headache is primarily based on
non-pharmacological measures. These are based on sparse
or no scientiﬁc evidence, and therefore the following rec-
ommendations are based on ‘‘expert opinion’’ [25].
• Identify and eliminate, to the extent possible, trigger
factors, e.g. stress and unphysiological work postures.
Physical activity may be beneﬁcial.
• Provide information on the factors causing tension-type
headache. It may be explained that each headache
episode can be caused by muscle tension or stress,
while chronic headache may also be caused by a
disturbance in the centres of the brain which regulate
pain.
• Physiotherapy should primarily comprise instruction on
how to maintain a correct work posture, correcting
posture in general and instruction, allowing the patient
to perform active exercises aimed at reducing muscu-
loskeletal tensions in the home. Controlled studies seem
to indicate that such measures have an effect [26].
• Behavioural and cognitive therapy (stress and pain
management) is typically performed by psychologists.
Table 9 Classiﬁcation of tension-type headache [1]
2.1 [G44.2/N95] Infrequent episodic tension-type headache
A. At least ten episodes occurring\1 day/month on average
(\12 days/year) and fulﬁlling criteria B–D
B. Headache lasting from 30 min to 7 days
C. Headache has at least two of the following characteristics:
1. Bilateral localisation
2. Pressing/tightening (non-pulsating) quality
3. Mild or moderate intensity
4. Not aggravated by routine physical activity such as climbing
stairs
D. Both of the following:
1. No nausea or vomiting (anorexia may occur)
2. No more than one of photophobia or phonophobia
E. Not attributed to another disorder
2.2 [G44.2/N95] Frequent episodic tension-type headache
As 2.1 apart from:
A. A minimum of ten episodes occurring C1 but\15 days/
month on average during C3 months (C12 and\180 days/year)
and fulﬁlling criteria B–D
2.3 [G44.2/N95] Chronic tension-type headache
As 2.1 apart from:
A. Headache occurring on C15 days/month on average for
[3 months (C180 days/year) and fulﬁlling criteria B–D
B. Headache lasts hours or may be continuous
D. Both of the following:
1. No more than one of photophobia, phonophobia or mild
nausea
2. Neither moderate/severe nausea nor vomiting
Table 10 Non-pharmacological treatment of tension-type headache
Physical examination and reassurance
Exclude other underlying disease, e.g. depression or
oromandibular dysfunction
Exclude overuse of analgesics
Inform the patient about disease mechanisms
Minimise, to the extent possible, trigger factors, e.g. stress and
unphysiological work postures
Physiotherapy (daily exercise programme and posture correction)
Biofeedback
Stress and pain management
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back (EMG and temperature) and cognitive techniques
(restructuring of negative thoughts, among others).
Treatment is focused on handling or coping with pain
and stress. Such treatment is only offered in a limited
number of places in Denmark. Controlled studies seem
to indicate that such treatments have an effect [27].
Biofeedback alone has a documented effect on tension-
type headache [8].
• Acupuncture is a frequently used measure. Controlled
trials of the effect of acupuncture on tension-type
headache have yielded diverging results [28].
• Manipulation of the cervical spine and blocking of the
greater occipital nerve (n. occipitalis major) showed no
effect in the few controlled studies performed.
4.5 Pharmacological treatment (see Table 11)
4.5.1 Attack treatment
The effect of mild analgesics during the individual epi-
sodes of tension-type headache is well established [29], but
the effect is often limited in patients with chronic tension-
type headache. The following treatments are recommended
[25]:
• ibuprofen 200–800 mg,
• ketoprofen 25 mg,
• acetylsalicylic acid 500–1,000 mg,
• naproxen 250–500 mg,
• diclofenac 12.5–100 mg,
• paracetamol 1,000 mg.
Controlled studies seem to indicate that NSAIDs are
more effective than acetylsalicylic acid, which in turn are
more efﬁcient than paracetamol [25]. Paracetamol is,
however, generally the medication which is tolerated best,
and many patients ﬁnd that the effect of the mild analgesics
is comparable. Consequently, the choice of analgesics
should be made on the basis of effect and side effects in the
patient in question. It is extremely important to assess if
there is any effect at all, or if the analgesics are rather taken
‘‘automatically’’ (‘‘to do something’’), and to set bound-
aries to avoid overuse.
Use of simple analgesics should not exceed 14 days/
month. Codeine and a range of combination medications
should, to the extent possible, be avoided and should only
be used 9 days/month to prevent medication overuse
headache (Sect. 6). Opioids should be avoided.
4.5.2 Prophylactic treatment
Prophylactic treatment may be indicated in patients with
chronic tension-type headache if the effect of non-phar-
macological treatment is insufﬁcient and when medication
overuse has been excluded [25]. Several placebo-controlled
studies have shown an effect of the tricyclic antidepressant
amitriptyline [30, 31], which is ﬁrst-line treatment in pro-
phylactic treatment of chronic tension-type headache. The
effect is independent of any concurrent depression.
The newer serotonergic and noradrenergic antidepres-
sants mirtazapine (30 mg/day) [31] and venlafaxine
(150 mg/day) [32] have both been reported to be effective
in a single study. These medications may be used with
advantage where amitriptyline has no effect or in cases
with concurrent depression. The effect of mirtazapine was
comparable to that of amitriptyline. No effect has been
documented from treatment with selective serotonin reup-
take inhibitors (SSRI), muscle relaxants or botulinum toxin
[25].
General guidelines:
• Inform thoroughly about the mechanisms of action
(particularly that antidepressants are not given on the
indication of depression) and about side effects.
• Provide slow dose escalation to minimise any side
effects.
• Use an adequately high dose.
• Monitor the effect achieved by using a headache
calendar.
• Assess the effect after 1–3 months at the ﬁnal dose.
• Attempt discontinuation every 6–12 months.
1. Amitriptyline tablets, 10–75 mg.
Effect: 30% reduction of the headache versus placebo.
• ECG should be checked before treatment initiation.
• 10 mg 91, increased by 10 mg/week until an effect is
achieved or until side effects occur [25].
Table 11 Pharmacological treatment of tension-type headache
Treatment of the individual episode (paracetamol, ASA, NSAID)
Avoid overuse of analgesics
Avoid opioids
Prophylactic treatment is considered in chronic tension-type
headache when non-pharmacological treatment has insufﬁcient
effect and medication overuse has been excluded
Amitriptyline, mirtazapine and venlafaxine have a prophylactic
effect
Be sure to inform the patient that antidepressants are given to
increase the concentration of pain-inhibitory substances in the
central nervous system and not to manage depression
Use a headache calendar to monitor treatment effect
Discontinuation of prophylactic medication should be attempted
every 6–12 months to conﬁrm that the patient still needs the
medication and that it remains effective
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between effect and side effects, is typically 30–50 mg.
• The entire dose should be given 1 h before bedtime to
improve sleep and minimise tiredness the following
day.
• Typical side effects include, among others, dry mouth,
fatigue, dizziness and weight gain.
2. Mirtazapine tablets, 15–30 mg.
Effect: 30% reduction of the headache versus placebo.
• 15 mg 91, increased to 30 mg 91 after a week.
• Administered approximately 1 h before bedtime.
• Typical side effects include, among others, fatigue,
weight gain and dizziness.
4.6 Summary
Tension-type headache is the most common of the primary
headache types and comprises a substantial health problem
in its frequent episodic and chronic forms. In episodic
tension-type headache, referred pain from the pericranial
musculoskeletal tissue and stress probably play an impor-
tant role, while an altered central pain modulation is
involved in the chronic form. A correct diagnosis is
important, particularly differentiation between episodic
tension-type headache and migraine. Comorbid factors,
e.g. depression, and secondary headache, e.g. medication
overuse headache, should be excluded.
Treatment is primarily based on non-pharmacological
measures including information, minimisation of trigger
factors, physiotherapy including posture correction and
instruction about active exercises, and stress and pain
management. The individual episodes may be treated with
mild analgesics.
In patients with chronic tension-type headache, analge-
sics rarely have an effect and, therefore, prophylactic treat-
ment with amitriptyline or mirtazapine may be indicated.
5 Cluster headache (Horton’s headache)
5.1 Diagnosis
Cluster headache, previously termed Horton’s headache,
occurs in a series of attacks, so-called clusters, typically
lasting 4–12 weeks. In between clusters, patients have
symptom-free periods of highly varying lengths (from
weeks to several years). Cluster headaches are severe,
unilateral headaches with burning and drilling pain around
or above one eye or temporally. In the majority of cases,
the same side is affected in all attacks (but the pain can
change sides). The pain typically has a duration of
45–90 min and may occur several times a day [33]. In
some patients, the attacks occur at roughly the same time of
day every day, and in others clusters occur at the same time
of every year. The pain is accompanied by ipsilateral
autonomic symptoms such as rhinorrhoea, lacrimation,
ptosis, miosis and oedema of the eyelid as signs of para-
sympathetic hyperactivity and sympathetic hypoactivity.
Patients are typically restless and agitated during attacks.
Attacks often occur at night, typically 1–2 h after the
patient has fallen asleep. Migraine-like symptoms such as
nausea, photophobia and phonophobia may also occur [33].
There are two types: episodic (80–90%) and chronic
(Table 12).
5.2 Background
Onset of cluster headache typically occurs at 20–40 years
of age and the condition has a prevalence of 80–100 per
100,000 persons [34]. Permanent remission is seen, but
after 15 years with the disease, 80% of patients still have
attacks [35]. Men have cluster headache ﬁve to seven times
more frequently than women. Cluster headache is one of
the most incapacitating types of headache [36].
The mechanism behind cluster headache is largely
unknown. It is possible that cluster headache is partially
caused by disturbances in the hypothalamus including
secondary activation of pain-sensitive nerves [33].
Table 12 Classiﬁcation of cluster headache [1]
3.1 [G44.0/N90] Cluster headache
A. At least ﬁve attacks fulﬁlling criteria B–D
B. Severe unilateral orbital, supraorbital and/or temporal pain
lasting from 15 to 180 min if untreated
C. Headache is accompanied by at least one of the following:
1. Ipsilateral conjunctival injection and/or lacrimation
2. Ipsilateral nasal congestion and/or rhinorrhoea
3. Ipsilateral oedema of the eyelid
4. Ipsilateral forehead and facial perspiration
5. Ipsilateral miosis and/or ptosis
6. A sense of restlessness or agitation
D. Attacks have a frequency from once every other day to eight
per day
E. Not attributed to another disorder
3.1. [G43.01/N89] Episodic cluster headache
A. Attacks fulﬁlling criteria A–E for 3.1 cluster headache
B. At least two cluster periods lasting 7–365 days and separated
by attack-free periods of C1 month
3.1.2 [G43.02/N89] Chronic cluster headache
A. Attacks fulﬁlling criteria A–E for 3.1 cluster headache
B. Attacks recur over[1 year without or with remission periods
lasting[1 month
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programme
In typical episodic cluster headache where the neurological
examination is normal, imaging is not mandatory, but in
atypical cases, treatment-refractory cluster headache and in
chronic cluster headache, a cerebral MRI scan should be
performed. Imaging is performed to exclude any space-
occupying processes or midline malformations [37]o r
pathology at the sinus cavernosus, the hypothalamus and
the pituitary gland [33]. The differential diagnosis regard-
ing the other attack-based trigeminal autonomic cephalal-
gias (TACs) is primarily made on the basis of attack
duration (see Table 13). Furthermore, a constant, unilateral
form of headache exists which has accompanying auto-
nomic symptoms, so-called hemicrania continua, which
responds to indomethacin. These types of headache are
very rare and will not be described further herein. For
further information, see the EFNS guidelines [37].
5.4 Non-pharmacological treatment
Generally, there is no effect of non-pharmacological
treatment on cluster headache [37].
5.5 Pharmacological treatment (see Table 14)
General recommendations:
• Treatment is generally a specialist assignment.
• Patients should receive medication against the acute
attacks and also prophylactic medical treatment.
• Prophylactic treatment is the most important form of
management and should be initiated as rapidly as
possible when a new cluster presents.
• For the majority of prophylactic medications, the dose
should be increased as quickly as possible.
• In case of total absence of attacks over a 14-day period
(notethatpatientsmayhavebriefattackswithautonomic
symptoms showing that the cluster has not ended), or
when the patient senses that a cluster has ended, tapering
of prophylactic medications should be attempted.
• Alcohol consumption may aggravate cluster headache
and should then be avoided in cluster periods. No other
trigger factors are known. Many cluster headache
patients are heavy smokers.
There is no evidence that smoking cessation alleviates
cluster headache.
5.5.1 Attack treatment
5.5.1.1 Oxygen inhalation Inhalation of pure (100%)
oxygen via a non-rebreathable facial mask with a ﬂow
between 7–10 and 7–12 l/min is an effective attack treat-
ment. Inhalation should be performed sitting in an upright
position. Such treatment is safe and has no side effects or
contraindications. Approximately, 60% of patients experi-
ence considerable pain relief within 30 min after inhalation
Table 13 Clinical characteristics of the trigeminal autonomic cep-
halalgias (TACs) [33, 37]
Cluster
headache
Paroxysmal
hemicrania
SUNCT
Epidemiology
Sex ratio, F:M 1:3–6 2–3:1 1:8–12
Prevalence (%) 0.9 0.02 Very rare
Age at onset
(years)
28–30 20–40 20–50
Pain
Type Drilling,
throbbing
Drilling Shooting
Intensity Very severe Very severe Intense/very
severe
Localisation Periorbital Orbital,
temporal
Orbital,
temporal
Attack
duration
15–120 min 2–45 min 5–250 s
Attack
frequency
1–8 per day 1–40 per day 3–200 per day
Autonomic
accompanying
symptoms
Yes Yes Yes
Effect of
indomethacin
No Yes No
Attack
treatment
Sumatriptan
injections/
spray, oxygen
None None
Prophylactic
treatment
Verapamil,
lithium,
prednisolone
Indomethacin Lamotrigine,
topiramate,
gabapentin
SUNCT short-lasting unilateral neuralgia, headache attacks with
conjunctival injection and tearing
Table 14 Pharmacological attack treatment and prophylactic treat-
ment of cluster headache
Medicinal product Dosage
Attack treatment
Pure oxygen, inhalation From 7 to 12 l/min
Sumatriptan injection 6 mg
Sumatriptan nasally 20 mg
Prophylactic treatment
Verapamil tablets 240–960 mg
Prednisolone 75 mg initially
Lithium According to serum values
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der ? mask) is supplied by private companies on prescrip-
tion from a department of neurology. Such equipment is
normally supplied on the day it is ordered. As this service is
relatively costly, the patient shouldonly have the equipment
for periods with cluster headache. Patients should contact
the oxygen company with a view to retrieving the oxygen
cylinder once their cluster period ends. There may be
regional differences in the rules concerning when oxygen
cylinders should be returned; for instance, patients in the
capital region are only required to hand in cylinders if the
cluster-free periods normally exceed a duration of 1 year.
5.5.1.2 Triptans Injection of sumatriptan 6 mg subcuta-
neous leads to complete pain relief in approximately 75%
of patients within 15 min [38] and is the ﬁrst-line treatment
for attacks if oxygen is ineffective or unavailable. Suma-
triptan nasal spray 20 mg [39] is also effective, but the
effect is achieved more slowly. Oral triptan formulations
generally take too long to gain effect [40]. Patients with
cluster headache are at risk of developing medication
overuse headache from frequent use of triptans. Common
side effects include a sensation of pressure on the chest,
nausea, distal paraesthesia and fatigue. Triptans are con-
traindicated in cases with uncontrolled hypertension,
ischaemic heart conditions, cerebrovascular conditions and
peripheral vascular diseases. Also see Sect. 3.5.1.2.
5.5.1.3 Other medications Standard analgesics are nor-
mally without effect.
5.5.2 Prophylactic treatment
5.5.2.1 Verapamil Verapamil is the ﬁrst-line prophylac-
tic treatment of cluster headache [41, 42]. There is no
scientiﬁc evidence on optimal dosing or on the use of
standard tablets versus prolonged-release tablets. Treat-
ment may, e.g. be initiated with tablets 80 mg 93,
increased by 80 mg/week.
The therapeutic dose is typically 240–480 mg a day. In
case of lack of effect, the dose should be increased by
100 mg with a minimum interval of 1 week. The daily dose
may need to be increased to 960 mg. ECG should be
checked before treatment initiation and repeated for every
200 mg increase when reaching doses above 400 mg daily.
Typical side effects are constipation, dizziness, ankle
oedema, tiredness, exanthema, hypotension and bradycar-
dia. Caution is advised in case of heart failure, AV block
and when combined with beta-blockers.
5.5.2.2 Prednisolone Prednisolone is used in episodic
cluster headache to achieve a rapid effect until other
prophylactic treatment has effect. Open studies have
demonstrated an effect [43]. The effect is often excellent,
but use is hampered by the severe side effects associated
with long-term treatment. The typical dosage is 75 mg 91
for 5 days followed by a 12.5 mg dose reduction daily until
discontinuation.
5.5.2.3 Lithium carbonate Lithium carbonate is primar-
ily used in chronic cluster headache, but may also be used
in the treatment of the episodic type. An effect has been
demonstrated for both types of cluster headache in a series
of open studies, while a placebo-controlled study failed to
demonstrate any effect in episodic cluster headache [37].
The typical dosage is tablet lithium carbonate 300 mg
(8.1 mmol) once daily increased after a week to one tablet
twice daily. Subsequently, the dosage is increased by one
tablet at 14-day intervals while monitoring serum lithium
levels. A serum concentration from 0.4 to 0.8 mEq/l has
been shown to be effective. Before treatment is initiated,
ECG, weight and blood samples [potassium, sodium, cre-
atinine, thyroid stimulating hormone (TSH)] should be
checked. Serum lithium is checked weekly during the ﬁrst
few weeks and then every 2–4 months. Serum creatinine
and TSH should be checked every 3–6 months. The typical
side effects are nausea, loose stools, polyuria, hand tremors
and weight increase.
5.5.2.4 Other prophylactic medicinal treatment Methy-
sergide and Ergocofﬁn may be used but are specialist
treatments. There are some reports on the effect of topi-
ramate, valproate and intranasal capsaicin.
5.5.3 Non-pharmacological prophylactic treatment
Blocking of the greater occipital nerve (n. occipitalis
major) can interrupt accumulated attacks and may have a
prophylactic effect for 4 weeks or more. An effect was
demonstrated in a single controlled trial [44]. Diprospane
solution for injection 2 ml ? 0.5 ml lidocaine 20 mg/ml
may be used. Diprospane 2 ml contains steroid corre-
sponding to 10 mg of betamethasone with protracted effect
and 4 mg of betamethasone with rapid onset. The block is
placed halfway between the inion (protuberantia occipitalis
externa) and the mastoid process, where the nerve is pal-
pable. It is relatively uncomplicated to apply the block and
not necessarily a specialist assignment. If an effect is
achieved, a block will typically remain effective for
3–4 weeks. A minimum of 3-month interval should sepa-
rate blocks to avoid connective tissue necrosis and alope-
cia. In special treatment-resistant cases, surgical insertion
of electrodes which continually stimulate the greater
occipital nerve bilaterally may be considered. This is only
performed at a very few centres worldwide and currently
not in Denmark. Furthermore, at a limited number of
J Headache Pain (2012) 13 (Suppl 1):S1–S29 S15
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hypothalamic region is offered [37].
5.6 Summary
Cluster headache is a relatively rare type of headache, but it
is very incapacitating and generally easy to diagnose.
Attack treatments as well as prophylactic management
generally have excellent effect. Consequently, it is essen-
tial that patients are diagnosed correctly so that they may
receive sufﬁcient treatment. Treatment is generally a spe-
cialist assignment.
6 Medication overuse headache
6.1 Diagnosis
Medication overuse headache (MOH) is a relatively fre-
quently occurring secondary headache caused by overuse
of analgesics and/or acute migraine medications [1]. MOH
is primarily seen as a complication to a pre-existing
headache condition.
MOH is deﬁned as a chronic headache ([15 days/
month) with concurrent intake of symptomatic medicine
for 15 days/month or more for simple analgesics/NSAIDs,
or intake of triptans, ergotamine or opioids for 10 days/
month or more during a 3-month period (Table 15)[ 45].
The typical MOH pattern is a gradually increasing
headache developing over weeks to months, particularly
with either an increased migraine frequency, awakening
headache or characteristic shifts even within a single
day from migraine to tension-type headache. The majority
of prophylactic measures, pharmacological as well as
non-pharmacological, are without effect where there is a
concurrent overuse of acute attack medication [46].
When the medications in question are discontinued, the
headache often recedes considerably in frequency and
intensity and returns to the original episodic pattern. The
headache then once again becomes susceptible to standard
treatment, and MOH patients are generally easy to treat
[47].
Medication overuse headache can also occur in patients
who are predisposed to headaches when analgesics are
taken for other indications, e.g. back pain or arthritis
conditions [48].
6.2 Background
MOH occurs in 1–2% of all adults and is increasingly seen
in children and adolescents. MOH was originally described
in 1951 by Peter and Horton of the Mayo Clinic, MN, USA
on the basis of ergotamine overuse [49]. MOH has subse-
quently been described regularly in association with all
analgesics including opioids and more speciﬁc migraine
drugs such as triptans [47, 48, 50, 51]. Combination drugs
containing codeine, caffeine and/or barbiturates generally
carry a higher risk of MOH than simple analgesics and
NSAIDs [47, 48, 50, 51].
The diagnostic distribution is very homogeneous across
studies: 65–70% of the patients had migraine as their pri-
mary diagnosis, 27–30% tension-type headache and 8–20%
had a combination of these or another type of headache.
The male/female ratio is 1:3.5, and the typical age at
onset is 30–40 years [48, 53, 54]. The mechanism behind
MOH is currently not known in detail, but upward
adjustment of central serotonergic and dopaminergic reg-
ulatory transmitter systems is involved.
6.3 Clinical assessment
The MOH diagnosis is made on the basis of a thorough
interview and a general physical and neurological exami-
nation. It is often necessary that the patient keeps a head-
ache diary including records of all medications taken for a
minimum period of 1 month. The differential diagnoses to
MOH are primarily chronic tension-type headache and
migraine and combinations hereof. Naturally, other sec-
ondary headache causes should be excluded; see Sects. 1, 2
and 7.
According to the criteria, the patient must have experi-
enced a minimum of 15 days with headache within the last
3-month period, but in practice these patients typically
present after many years with daily headaches and frequent
migraine-like attacks [48, 50, 53]. According to the criteria,
the headache must have developed during the medication
overuse period, or the primary headache shall have
aggravated markedly, but it is often difﬁcult to obtain this
information as these chronic headaches may have persisted
for a very long period of time.
Table 15 Diagnostic criteria for medication overuse headache [45]
A. Headache present on C15 days/month
B. Regular overuse for[3 months of one or more acute/
symptomatic treatment drugs as deﬁned under subforms of 8.2
medication overuse headache
1. Ergotamine, triptans, opioids or combination analgesics
C10 days/month on a regular basis for[3 months
2. Simple analgesics or any combination of ergotamine, triptans
or opioids for C15 days/month on a regular basis for[3 months
without overuse of any single class alone
C. Headache has developed or markedly worsened during
medication overuse
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6.4.1 Non-pharmacological
The essential elements of treatment are training and
information along with support and treatment of any
withdrawal symptoms (Table 16). The next step is dis-
continuation of all analgesics. Alternatively, attack medi-
cation may be reduced to a maximum of 2 days/week. It is
unknown which approach works best. Patients should be
informed that after discontinuation of analgesics, some
develop withdrawal symptoms and rebound headache with
migraine-like headaches and in some cases nausea, vom-
iting sleep disturbances, agitation, anxiety, nervousness,
hypotension and tachycardia. These symptoms have a
duration of 2–10 days depending on the type of medication
causing the overuse: 2–3 days for triptans and 8–10 days
for pharmaceuticals containing codeine or ergotamine
[52, 53, 55]. As withdrawal symptoms recede, the patients
may notice a spontaneous improvement of their headache
over the following weeks to months. Many patients also
experience a considerable general improvement of their
condition as they are no longer affected by a daily medi-
cine intake. During the process, support and understanding
from relatives, the patient’s employer and GP are important
during the entire withdrawal period. A notiﬁcation of ill-
ness lasting 2–3 weeks will often be recommendable. It
may be necessary to refer the patient to specialist treatment
or to admit the patient to a neurology department in case of
marked overuse, use of opioids, signiﬁcant comorbidity
or previous unsuccessful treatment courses [52, 53, 55];
see Table 16.
6.4.2 Pharmacological treatment
Support medicine may be needed during the ﬁrst
1–2 weeks. The following may be used:
• levomepromazine 12.5–25 mg maximally three times a
day for a week followed by rapid tapering off or
• promethazine 25 mg maximally three times a day for a
week followed by rapid tapering-off;
• metoclopramide suppositories 20 mg in case of nausea,
maximally three times a day for a week, then discon-
tinuation (see Table 17).
6.5 Prophylactic treatment
6.5.1 Non-pharmacological
The objective of the treatment is to achieve abstinence from
analgesics or a reduction in the intake of attack medication to
a maximum of 2 days/week during an 8-week period.
Patients should be informed that improvements may occur
gradually and be permanent. Hereby, the chronic headache
and behavioural pattern is interrupted and the headache
resumes the typical attack pattern or recedes completely.
Relaxation, bed rest and plenty of ﬂuids are recommended
andpatientsoftenexperiencethatattacksrecedeconsiderably
and may be managed without analgesics. After the 2 months
have passed, a restrictive intake of analgesics or migraine
Table 16 Non-pharmacological treatment of medication overuse
headache
The primary treatment elements:
Abrupt discontinuation of all analgesics and acute migraine
medicine or a reduction of the intake of attack medication to a
maximum of 2 days per week during a 2-month period
Training and information to patients as well as relatives and
medical staff
Psychological support, information and treatment of any
withdrawal symptoms such as severe headache, nausea,
vomiting, sleep disturbances, increased sweating, agitation,
anxiety, nervousness, hypotension and tachycardia for 2–10 days
depending on the type and amount of medicine taken
Admission to a neurology department in cases with considerable
medication overuse and/or signiﬁcant comorbidity
A sick leave of 2–3 weeks is recommended
Follow-up with GP for 6–12 months
Spontaneous and marked reduction of headache over weeks to
months. Many patients also experience a considerable general
improvement of their general condition as they are no longer
affected by a daily medicine intake
Table 17
Pharmacological treatment of medication overuse headache
Support medicine may be needed during the ﬁrst week and the
following may then be used:
• Levomepromazine 12.5–25 mg as needed maximally three times
per day or promethaxine 25 mg x as needed maximally three
times per day for a week followed by rapid tapering off
(1–2 weeks)
• Metoclopramide suppositories 20 mg in case of severe nausea
and vomiting
• Phenobarbital 100–200 mg 9 2–3 for the ﬁrst 4–5 days in case
of severe withdrawal symptoms after discontinuation of opioids/
combination medicines. After opioid overuse, methadone 20 mg
may be needed and should then be tapered off over a 4-day
period
After 2 months
• Initiation of prophylactic medication in accordance with
standard guidelines depending on the type of headache
• Thorough information to the patient on the correct use of acute
and prophylactic medical treatment
• Previously used medication, which during the medication
overuse period had no effect, may now have effect
• Close follow-up at GP or specialist to avoid relapse into
medication overuse
• Limited re-initiation of attack medication
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medication intake in a headache calendar and frequent visits
to the GP are important to prevent recurrence of MOH.
6.5.2 Pharmacological
In case of a high attack frequency, it is necessary to initiate
standard prophylactic treatment and it should be stressed
that preventive medicine which proved ineffective during
the medication overuse period may now again have
become effective [47]. The choice of medication depends
on the primary headache type, previous adverse event
proﬁle and any comorbidity.
6.6 Summary
MOH is a rather frequently occurring secondary headache
conditioncausedbyoveruseofanalgesicsandacutemigraine
medication. The treatment course may be protracted and
difﬁcult to complete, but the result is very positive and pre-
viously treatment-refractory patients may present with sig-
niﬁcantly reduced attack frequencies and intensities after
medicine review. MOH is a condition which in principle can
and should be prevented through general information to
patients and a restrictive prescription behaviour.
7 Secondary types of headache
7.1 Diagnosis
Secondary headache is deﬁned as one which presents with
a close temporal association to another condition which
may cause the headache.
According to the ICHD-II [1], secondary headache is
divided into the following groups:
• headache following head and neck trauma;
• headache related to cranial or cervical vascular
conditions;
• headache related to non-vascular conditions;
• headache related to intake of substances or discontin-
uation of such intake;
• headache related to infections;
• headache related to homoeostatic disturbances;
• headache or facial pain in relation to dysfunction of the
cranium, neck, eyes, nose, sinuses, teeth, mouth or
other facial or cranial structures.
7.2 Background
In addition to the previously mentioned primary types of
headache, headache may also occur as the ﬁrst symptom
of serious life-threatening disease. Even though these
serious conditions comprise far \1% of all types of
headache, a newly onset severe headache commands
extra attention and thorough diagnosis [56–58]. Where
there is a close temporal relation to a head trauma or
systemic disease, the development of the headache should
be followed closely during admission or regularly by the
GP.
In the general population, approximately 2% have sec-
ondary headache [56–58] and among these the vast
majority suffer from medication overuse headache induced
or maintained by overuse of analgesics or speciﬁc migraine
medication [56, 57]. The prognosis is generally good, as
the headache tapers off after reduction of medicine intake
[59]; see Sect. 6. The temporal development of headache is
the key to diagnosis [60, 61]. A ‘‘crack’’ in the head
combined with maximal pain intensity after seconds should
always raise suspicion of a subarachnoid haemorrhage,
while a progressive headache with subacute onset follow-
ing a head trauma may be the ﬁrst symptom of increased
intracranial pressure and of an epidural haematoma which,
if left untreated, may develop into a life-threatening con-
dition over the course of few hours.
Subacute headache which has developed over 1–2 days
and is accompanied by fever, malaise and possibly seizures
may indicate a cerebral sinus vein thrombosis, meningo-
encephalitis or a cerebral abscess. A headache with gradual
onset which has developed over weeks to months accom-
panied by any epileptiform attack elements, personality
changes, speech disturbances and/or hemiparesis may be
caused by a space-occupying cerebral tumour or a chronic
subdural haematoma.
7.3 Special assessment programme
The medical history and physical neurological examination
are fundamental elements in the identiﬁcation of any
serious secondary headache. A thorough neurological
examination, including ophthalmoscopy and measurement
of temperature and blood pressure, is essential for the
diagnosis of serious secondary types of headache. In
addition to the mandatory neurological examination, the
assessment programme depends heavily on the onset and
course of the headache.
In headaches with subacute or acute onset, the following
may be indicated: CT or MRI scans of the cerebrum, MRI
or CT angiography and venography [60, 61] and lumbar
puncture with analysis of the CSF for cells, glucose and
protein and pressure measurement.
In slowly progressing headache developing over weeks
to months, there may be indication for CT or MRI scans of
the cerebrum, and—if the neuroradiological examination is
negative—for CFS analysis as stated above [60, 61].
S18 J Headache Pain (2012) 13 (Suppl 1):S1–S29
1237.4 Clinical assessment
Warning signals identiﬁed from the history or the physical
examination that warrant further examination:
• thunderclap headache (severe headache with sudden
onset);
• headache with atypical aura (lasting more than 1 h or
including motor symptoms);
• newly presenting headache in an HIV or cancer patient;
• headache/facial pain accompanied by fever or neuro-
logical symptoms;
• progressive headache lasting for weeks;
• newly presenting headache in patients below the age of
10 years or above 40 years.
It is important to acknowledge the symptoms of the
severe secondary headache types. Please refer to general
text books for further information, but we would like to
stress the following forms:
Subarachnoid haemorrhage should be suspected in case
of:
• thunderclap headache with acute onset;
• possibly initiated by a generalised seizure;
• possibly followed by affection of consciousness.
Temporal arteritis
• Typically occurs above 50 years of age;
• typical symptoms: headache and constitutional
symptoms;
• tenderness on palpation of the temporal artery;
• jaw claudication (up to 40%);
• amaurosis fugax (approximately 10%), which may lead
to blindness if left untreated;
• sedimentation rate exceeding 50 mm/h (only 3% have a
normal SR);
• biopsy of the temporal artery tests positive in 50% of
the cases;
• treatment should be initiated on clinical suspicion
before any biopsy results are available.
Primary glaucoma
• Headache may be a symptom in narrow-angle
glaucoma;
• rarely occurs before the age of 50 years;
• risk factors: family predisposition, female sex and
myopia;
• the condition may present as ocular hypertension;
• painful red eye;
• semi-dilated pupil with no reaction to light;
• accompanied by nausea and vomiting;
• complaints of blurred vision and coloured rings around
light objects.
Sinus vein thrombosis
• Gradually increasing headache with subacute onset is
the presenting symptom in 70% of cases [64];
• ﬂuctuating neurological symptoms:
1. paresis (60%),
2. papilloedema (30–60%),
3. meningitis (25–30%),
4. reduced level of consciousness (60%),
5. epileptic seizures (40–50%).
Idiopathic intracranial hypertension (other names:
benign intracranial hypertension and pseudotumor cerebri)
[63]:
• Rare cause of chronic headache in slim persons (1–2/
100,000), but seen 20–40 times more frequently in
overweight persons;
• may lead to permanent visual ﬁeld defect or blindness if
left untreated;
• typically seen in younger women;
• may be conditioned by severe obesity;
• the typical signs are headache, papilloedema, abducens
paralysis (the affected eye cannot be moved tempo-
rally) and or pulsating tinnitus;
• on suspicion, admission is necessary (important differ-
ential diagnosis: sinus vein thrombosis) and neuroradio-
logical assessment, i.e. measurement of the cerebrospinal
pressure, which will have increased[25 cmH2O.
Other secondary types of headache
• Cerebral tumour;
• chronic post-traumatic headache;
• dissection of the carotid, vertebral or basilar artery;
• severe arterial hypertension and hypertensive
encephalopathy;
• neuroinfection or severe systemic infection (including
sinusitis);
• Arnold Chiari malformation;
• hydrocephalus;
• postlumbarpunctureheadacheorspontaneousduralesion.
7.5 Treatment
Treatment depends on the diagnosis.
8 Trigeminal neuralgia
8.1 Diagnosis
In the majority of cases, trigeminal neuralgia (TN) is a
unilateral condition with ultra-short stabbing pain located
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(Table 18). Numerous daily attacks may occur. The attacks
are stereotypical in the individual patient. Trigeminal
neuralgia most frequently presents in the second or third
branch and is often misinterpreted as originating from teeth
or sinuses. The pain is often triggered by stimuli such as
chewing, washing of the face, speech, tooth-brushing,
shaving and cold winds, but also occurs without any
stimuli. Often, there are trigger points in the face. Pain may
be intermittent. The condition may aggravate or recede
completely for weeks to months and, in rare cases, years.
Autonomic symptoms usually do not occur (see Sect. 5).
The diagnostic criteria [1] for classic TN are shown in
Table 19. Symptomatic TN is caused by a structural lesion
(apart from neurovascular contact (a vessel, typically
leading to the cerebellum, exercising pressure on the tri-
geminal nerve)). There is no safe way to distinguish
between classic and symptomatic TN on the basis of pain
characteristics or therapeutic effect. Atypical facial pain
does not have the neuralgiform characteristics seen in TN,
but is often a more constant, diffuse pain.
8.2 Background
Trigeminal neuralgia most frequently presents after the age
of 50 years and affects slightly more women than men.
Approximately, 200–250 new cases are seen in Denmark
annually [64]. TN may be caused by compression of the
trigeminal nerve, most frequently near its connection to the
brainstem. Compression is frequently caused by a minor
artery leading to the cerebellum. This causes demyelination
of the nerve root and subsequently ephaptic impulse for-
mation with cross-excitation of the neighbouring ﬁbres (in
plain English: short-circuiting of the nerve ﬁbres). TN is
furthermore seen in multiple sclerosis and in idiopathic
cases [65].
8.3 Clinical assessment
A thorough medical history and a detailed neurological
examination are essential to reach the correct diagnosis.
Sensory symptoms from the affected nerve branch and
bilateral pain raise suspicion of secondary TN [66]. Age at
onset of TN involving the ﬁrst trigeminal branch or lack of
effect of medicinal treatment cannot be used to identify
symptomatic TN [64]. In patients with TN and no other
symptoms, there is a symptomatic cause (in addition to
neurovascular contact) in up to 15% of cases [64]. There-
fore, a cerebral MRI scan should be performed to visualise
any neurovascular contact and to exclude any secondary
cause (e.g. multiple sclerosis, tumours).
8.4 Non-pharmacological treatment
A limited number of patients report effect from acupunc-
ture, but there is no scientiﬁc evidence to support an effect
of such or other non-pharmacological treatment.
8.5 Pharmacological treatment
8.5.1 Acute treatment
The effect of standard analgesics and opioids is usually
very limited. In severe trigeminal neuralgia where acute
intervention is needed, infusion of phenytoin or lidocaine
may be attempted during admission.
8.5.2 Prophylactic treatment
Prophylactic treatment with anti-epileptics has a stabilising
effect on the nerve and is effective in the majority of
cases—at least initially [66] (Table 20). As TN often has a
periodic course, the dose should be adjusted continually
according to the effect achieved and side effects observed.
Table 18 Characteristics of trigeminal neuralgia
In the majority of cases, trigeminal neuralgia is a unilateral
condition with ultra-short stabbing pain located along one or
more branches of the trigeminal nerve
Onset is most often located to the second or third branch
Onset typically occurs after 50 years of age
The pain is often triggered by stimuli such as chewing, washing of
the face, speech, tooth-brushing, shaving and cold winds, but
also occurs without any stimuli. Often, there are trigger points in
the face
Pain may be intermittent. Consequently, the condition may
aggravate or recede completely for weeks to months, and in rare
cases, years
Symptomatic trigeminal neuralgia may, e.g. be caused by space-
occupying processes of the fossa posterior and by multiple
sclerosis. If the cause is pressure from vessels of the
cerebellopontine angle, the case is diagnosed as classical and
non-symptomatic trigeminal neuralgia
Table 19 Diagnostic criteria of trigeminal neuralgia
13.1 [G50.00/N92] Classic trigeminal neuralgia
A. Paroxysmal attacks of pain lasting from a fraction of a second
to 2 min, affecting one or more divisions of the trigeminal nerve
and fulﬁlling criteria B and C
B. Pain has at least one of the following characteristics:
1. Intense, sharp, superﬁcial or stabbing
2. Precipitated from trigger areas or by trigger factors
C. Attacks are stereotyped in the individual patient
D. There is no clinically evident neurological deﬁcit
E. Not attributed to another disorder
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but there is no scientiﬁc evidence to support the effect
hereof [64]. There are no good scientiﬁc studies of phar-
macological treatment of symptomatic TN [64], which is
therefore treated in accordance with the guidelines of
classic TN.
1. Carbamazepine.
Effect It is the only medication for which an effect has
been demonstrated in several controlled studies. Approxi-
mately, 60–70% of patients achieve a minimum 50% pain
reduction. The number needed to treat to achieve a sub-
stantial pain relief is 1.7–1.8 [64]. The effect is often ham-
peredbysideeffects(thenumberneededtoharmis3.4)[64].
• The initial dose is 200–400 mg daily given as twodoses,
increased by 100 mg every second day until pain relief
or signiﬁcant side effects. The typical maintenance dose
is 200–600 mg/day given as two or three doses.
• Daily doses of up to 2,400 mg may be necessary.
• Once the maintenance dose has been established, the
patient should be treated with two daily doses given as
prolonged-release tablets.
2. Oxcarbazepine may also be a ﬁrst-line medication.
Effect Comparative studies seem to show that the effect
is comparable to that of carbamazepine [64].
Oxcarbazepine is often tolerated better than carbamaz-
epine (66).
• The initial dose is 300–600 mg daily given as two
doses, increased by 300 mg every second day until pain
relief or signiﬁcant side effects.
• The typical maintenance dose is 600–1,800 mg/day
given as two or three doses.
• Daily doses of up to 2,400 mg may be necessary.
3. Gabapentin may be used in combination with carba-
mazepine/oxcarbazepine or as monotherapy.
Effect No certain documented effect.
• The initial dose is 300 mg once daily increased by
300 mg daily until an effect is achieved or signiﬁcant
side effects are observed. The maximum dose is
3,600 mg daily divided into three doses
• The typical maintenance dose is 600–2,400 mg daily
4. Baclofen may be used to supplement carbamazepine/
oxcarbazepine or as monotherapy.
Effect An effect was reported in two small studies.
• The initial dose is 10 mg daily given as two doses,
increased by 5 mg every third day until pain relief or
signiﬁcant side effects.
• The typical maintenance dose is 30–80 mg/day given
as three or four doses.
5. Lamotrigine may be used to supplement carbamaze-
pine/oxcarbazepine or as monotherapy.
Effect A single study has demonstrated an effect in
combination with carbamazepine/oxcarbazepine.
• Theinitialdoseis25 mgoncedailyfor2 weeksfollowed
by50 mgdailyfor2 weeks,followedby50 mgtwiceper
day for 2 weeks. Thereafter, if needed, the dose may be
increased by 50 mg/week until an effect is achieved or
signiﬁcant side effects are observed.
• The typical maintenance dose is 200–400 mg/day given
as two doses, and in some cases 500 mg daily.
6. Valproate may be attempted as monotherapy or in
combination with other medications.
Effect A few small studies seem to show an effect.
• The initial dose is 1,000 mg 91 and, subsequently, if
needed, dose adjustment of 500–1,500 mg once daily is
made.
7. Phenytoin may be used to supplement carbamazepine/
oxcarbazepine or as monotherapy.
Effect An effect was reported in uncontrolled studies.
• The initial dose is 5 mg/kg divided into two doses.
• The typical maintenance dose is 200–400 mg/day given
as two doses.
• Inexpedient in long-term treatment due to serious long-
term side effects.
8. Pregabalin may be attempted as monotherapy or in
combination with other medications.
Effect An effect was reported in uncontrolled studies.
• The initial dose is 150 mg daily given as two doses,
increased by 150 mg a week to a maximum of 600 mg
daily.
• The typical maintenance dose is 150–600 mg/day given
as two to three doses.
Table 20 Treatment of trigeminal neuralgia
Primarily prophylactic pharmacological treatment with anti-
epileptics
Normally, weak analgesics and opioids have no effect
Spontaneous remission is frequent. If the patient has been pain-
free for 3–4 weeks, gradual discontinuation of medical
management may be considered
In case of acute aggravation, where the patient has problems
ingesting food, attacks may be interrupted with a fosphenytoin or
lidocaine infusion
In case of unsatisfactory effect from medical treatment, a decision
should be made with regard to neurosurgical treatment
(microvascular decompression or lesion treatment)
The decision on neurosurgical treatment should be made as
quickly as possible to avoid development of a chronic
neuropathic pain condition.
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In approximately 30% of patients, medical treatment is
inadequate. In these patients, surgical treatment should be
considered. It should be determined as quickly as possible
if a patient can be treated adequately with pharmaceuticals
or if surgery should be offered, as prolonged symptoms
increase the risk of developing constant background pain
and of loss of sensibility in the trigeminal area.
8.6.1 Microvascular decompression
Microvascular decompression is the most effective treat-
ment [64]. In microvascular decompression, a retromastoid
craniotomy is performed after which the vessel(s) com-
pressing the nerve are dissected off. Approximately 90% of
cases experience a good initial effect, 80% are pain-free
after a year and 73% are pain-free after 5 years [64]. The
perioperative mortality ranges from 0.2 to 0.5%, and up to
4% have serious side effects such as haematoma, CSF
leakage or infarction. The most frequent side effect is
ipsilateral hearing loss, which is seen in up to 10% of cases
[64]. Dysaesthetic pain and loss of sensibility are seen in a
small number of patients. There is no evidence to support
the use of MRI scans to identify those patients who would
beneﬁt from microvascular decompression [64].
8.6.2 Lesion treatment
Lesion treatment may be used in patients who are unsuited
for microvascular decompression surgery. Glycerol is
injected under local anaesthesia to the trigeminal ganglion.
Glycerol injection destroys the cell bodies in the ganglion.
Thermocoagulation and balloon compression are other
forms of lesion treatment offered in Denmark. Approxi-
mately, 68–85% of cases remain pain-free after a year, and
50% are pain-free after 5 years [64]. Lesion treatment may
be repeated in case of lacking effect or relapse. Approxi-
mately, 4% develop severe dysaesthesia (anaesthesia do-
lorosa) [64]. Lesion treatment, then, is less invasive than
microvascular decompression, but also has a lower success
rate and a higher recurrence rate.
8.7 Summary
In the majority of cases, trigeminal neuralgia is a unilateral
condition with ultra-short stabbing pain located along one
or more branches of the trigeminal nerve. The pain is often
triggered by stimuli such as chewing, washing of the face,
speech and tooth-brushing. Trigeminal neuralgia is pri-
marily caused by compression of the nerve near its origin at
the pons. The treatment consists primarily of prophylactic
pharmacological treatment with anti-epileptics. In case of
insufﬁcient effect or unacceptable side effects, neurosur-
gical treatment using microvascular decompression or
lesion treatment should be considered.
9 Hormones and migraine
This section describes the particular conditions associated
with migraine in relation to menstruation, hormonal treat-
ment, pregnancy and breast-feeding.
9.1 Diagnosis
Menstrual migraine is deﬁned as migraine attacks occur-
ring on the ﬁrst menstrual day ± 2 days in a minimum of
two out of three menstrual cycles [1]. Menstruation is
deﬁned as endometrial haemorrhage associated with either
a normal menstrual cycle or discontinuation of added
female sex hormone, e.g. from oestrogen-containing con-
traceptive pills and cyclic hormone therapy.
The overwhelming majority of women also have
migraine attacks at points in time that are unrelated to their
menstrual cycle. In such cases, migraine is classiﬁed as
menstrually related migraine. If attacks occur exclusively
in connection with menstrual periods, the condition is
deﬁned as pure menstrual migraine.
9.2 Background
The occurrence of migraine is associated with the men-
strual cycle. This is particularly pronounced for migraine
without aura [67]. Migraine is equally frequent in pre-
adolescent girls and boys, but approximately three times as
many women as men have migraine after puberty.
Migraine may be triggered by a sudden drop in the oest-
rogen level, but only if the level has previously remained
high for several days [68]. This explains why migraine
occurs more frequently at menstrual periods and less fre-
quently during pregnancy. There is, however, no certain
association with ovulation. Around menopause, some
women experience an aggravation of their migraine [69].
After menopause, both the incidence [70] and the preva-
lence [71] of migraine decrease.
9.3 Speciﬁc risk factors
The risk of cerebral infarction is approximately doubled in
women with migraine with aura compared with the back-
ground population. If these women are under 45 years and
are smokers or take oestrogen-containing contraceptive
pills, the risk is considerably higher. As cerebral infarction
occurs rarely in young persons, it is difﬁcult to quantify the
increase in relative risk [72]. However, it is now considered
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at an increased risk of cerebral infarction. It is important to
put this into perspective, as the absolute risk of cerebral
infarction remains small in young women with migraine
(18 cases per 100,000 female years).
In one study, an overweight of cardiovascular risk fac-
tors was found in patients with migraine [73], but the
causes of the increased risk of cerebral infarction in women
with migraine with aura remain unknown. Women above
45 years of age with migraine without aura do not have an
increased risk of cerebral infarction [74]. Migraine with
aura is thus a risk factor for cerebral infarction in women,
and the risk is more pronounced in women below 45 years
of age who are smokers and who take oestrogen-containing
contraceptive pills [75]. In women suffering from migraine
with aura it is essential, to the extent possible, to reduce
other known and modiﬁable risk factors for cardiovascular
disease (hypertension, hypercholesterolaemia, smoking,
etc.) [76]. Contraceptive measures without systemic oest-
rogen contents should be used [1, 6, 7]. However, most
experts do not consider that oestrogen-containing contra-
ceptive pills are an absolute contraindication if there are
substantial reasons to choose these [77]. For such treat-
ment, contraceptive pills with the lowest possible oestrogen
contents should be used, and the patient should be informed
of the increased risk. Hormonal contraceptives only con-
taining progesterone do not increase the risk of cerebral
infarction [78]. Young women who have migraine with
aura are strongly encouraged not to smoke. Women who
have migraine with aura should be informed that they have
a slightly increased risk of a blood clot in the brain, but that
the risk is very limited if no other risk factors exist and if
they abstain from smoking and from taking oestrogen-
containing contraceptive pills. Consequently, for the
overwhelming majority of these patients, migraine is a
benign if bothersome condition with a good prognosis.
9.4 The effect of hormone treatments on migraine
There are no well-executed prospective studies which show
how contraceptive pills affect migraine occurrence. Two
retrospective studies reported that 24–35% of women with
migraine experienced an aggravation, 5% an improvement
and 44–65% no change in their migraine during treatment
with contraceptive pills [79]. In a recent, population-based
study from Norway, an increased occurrence of migraine
was found among women taking oestrogen-containing
contraceptive pills [79]. The overall conclusion is that
contraceptive pills often have no impact on the course of
migraine, but when there is an impact, it is generally an
aggravation.
Cyclic oestrogen treatment in connection with men-
struation was reported to have some beneﬁcial effect in a
limited number of small studies, but such effect could not
be conﬁrmed in a recent placebo-controlled study [80].
When there is a need for hormonal substitution treatment,
continuous treatment with transdermal oestrogen should be
preferred, as in the majority of cases this does not aggra-
vate migraine in contrast to oral hormone treatment [68].
Surgical procedures such as bilateral oophorectomy can
generally not be recommended as these aggravate migraine
in most cases [81].
9.5 Treatment of menstrual migraine
The principles of non-pharmacological treatment and
attack treatment in menstrual migraine do not differ from
those of non-hormone associated migraine. Menstrual
migraine, however, tends to be more difﬁcult to treat than
migraine which is not associated with menstruation [80].
Prophylactic treatment of menstrual migraine.
• Menstrual migraine may be treated by not stopping the
use of contraceptive pills for several cycles, e.g. by
taking contraceptive pills continuously for 9 weeks
(instead of the standard 3 weeks), followed by a 7-day
period without contraceptive pills [2]. If breakthrough
bleeding occurs earlier, the pill-free period is taken
when the bleeding occurs.
• Alternatively, cyclic prophylaxis may be used, i.e.
6 days of treatment starting 2 days before the ﬁrst
menstrual day (or before the pill-free phase for women
who are taking contraceptive pills). Treatment consists
of the following:
• NSAID, e.g. naproxen tablets 500 mg twice daily [21];
• OR frovatriptan tablets 2.5 mg twice daily. These
should be given with caution due to the risk of
medication overuse headache;
• OR brief dose increase of habitual prophylactic
medication;
• OR magnesium tablets 360 mg once daily—it is not
given as described above, but starting 15 days after the
ﬁrst menstrual day and ending when the next period
starts;
• Cyclic prophylaxis should, as a minimum, be attempted
for three cycles before concluding whether the treat-
ment is effective.
• The scientiﬁc evidence to support these treatments is
limited.
9.6 Pregnancy
The patient is advised to be patient, as the migraine will
end or recede considerably during pregnancy in 70% of
patients. In the overwhelming majority of cases, migraine
recurs after birth or at the end of the breast-feeding period.
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• To the extent possible, non-pharmacological treatment
including relaxation, bed rest, ice packages, etc.
• If pharmacological treatment is needed, paracetamol is
the ﬁrst-line treatment.
• NSAID medications should be avoided.
• Sumatriptan may be used. There are data from more
than 2,000 ﬁrst-trimester exposures showing no signs of
any excess incidence of unwanted foetal affection.
A register study found three cases of oesophagus atresia
in a group of 1,718 persons where the normal frequency
was approximately 1/5,000. This may be a coincidence,
but if there is an association, the risk is very low. The
other triptans should be avoided.
• Caution is necessary in connection with the adminis-
tration of metoclopramide in the ﬁnal trimester. The
antihistamine meclozine 25–50 mg 92 may also be
used against nausea, though not in the two ﬁnal weeks
before term
• Codeine medication must be avoided due to
teratogenicity.
• Ergotamine is contraindicated due to its uterus-con-
tracting effect.
Prophylactic treatment
• Note that migraine will often improve during
pregnancy.
• Prophylactic treatment should be avoided if possible.
• Some experts state that propranolol, metoprolol, ami-
triptyline and magnesium may be used with caution [2,
10], but this remains controversial.
9.7 Breast-feeding
Acute treatment
• To the extent possible, non-pharmacological treatment
including relaxation, bed rest, ice packages, etc. may be
used.
• If the above have been attempted and are insufﬁcient,
• paracetamol and some NSAIDs may be used;
• sumatriptan may be used. Breastfeeding should be
avoided for at least 24 h after intake of the other
triptans. The milk for the next 24-h period may, e.g.
be pumped out before taking any of the other
triptans.
• Caution must be exercised with use of metoclopramide.
• ASA, benzodiazepines and ergotamine must be
avoided.
Prophylactic treatment
• Pharmacological prophylaxis to the extent possible
must be avoided.
• Valproate and amitriptyline may be used.
10 Children and headache
10.1 Diagnosis
Diagnosis of headache in children follows the ICHD-II
criteria used in adults with some modiﬁcations (see foot-
notes of Table 21). This section focuses on the character-
istics speciﬁc to children.
Table 21 Classiﬁcation of headache in children
1.1 [G43.0/N89] Migraine without aura
A. A t least ﬁve attacks fulﬁlling criteria B–D
B. Headache attacks lasting from 4 to 72 h
a
C. Headache has at least two of the following characteristics:
1. Unilateral localisation
b,c
2. Pulsating quality
3. Moderate or severe pain intensity
4. Aggravation by or causing avoidance of routine physical activity such as climbing stairs
D. During headache at least one of the following:
1. Nausea and/or vomiting
2. Phono- and photophobia
d
E. Not attributed to another disorder
1.2 [G43.1/N89] Migraine with aura
Children and adults share the same diagnostic criteria
1.3.1 [G43.82/N89] Cyclic vomiting
A. At least ﬁve attacks fulﬁlling criteria B–C
B. Episodic attacks, stereotypical in the individual patient, of intense nausea and vomiting
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Migraine in children differs from migraine in adults, par-
ticularly due to the following:
• shorter duration of attacks;
• more common bilateral localisation;
• distinct gastrointestinal symptoms.
The speciﬁc periodic syndromes which occur in children
(cyclic tendency to vomit, abdominal migraine or benign
paroxysmal vertigo) may be precursors to adult migraine,
but these conditions are relatively rare. Other primary types
of headache such as tension-type headache and cluster
headache may also present in early childhood, even though
onset is more common around adolescence, but the
symptoms of these conditions do not otherwise differ from
the symptoms seen in adults; see Sects. 4 and 5.
Headache caused by medication also occurs in children
and adolescents, but is no different from that caused by
medication in adults (see Sect. 5). Generally, children with
headache should not receive attack medication more than
two times a week.
Table 21 continued
lasting from 1 h to 5 days
C. Vomiting during attacks occurs at least four times per hour for at least 1 h
D. Symptom-free between attacks
E. Not attributed to another disorder
e
1.3.2 [G43.820/N89] Abdominal migraine
A. At least ﬁve attacks fulﬁlling criteria B–D
B. Attacks of abdominal pain lasting 1–72 h (untreated or unsuccessfully treated)
C. Abdominal pain with all of the following characteristics:
1. Midline localisation, periumbilical or poorly localised
2. Dull or ‘‘just sore’’ quality
3. Moderate or severe intensity
D. During the abdominal pain at least two of the following:
1. Anorexia
2. Nausea
3. Vomiting
4. Pallor
E. Not attributed to another disorder
f
The attacks are not caused by another condition
f
1.3.3 [G43.821/N89] Benign paroxysmal vertigo of childhood
A. At least ﬁve attacks fulﬁlling criterion B
B. Multiple episodes of severe vertigo
g, occurring without warning and resolving spontaneously after a few minutes to hours
C. Normal neurological examination and audiometric and vestibular functions between attacks
D. Normal electroencephalogram
2. [G44.2/N95] Tension-type headache
Children and adults share the same diagnostic criteria
a In children\15 years of age, the duration of an attack may be 1–72 h; the duration of untreated headache in children with a duration below 2 h
should, however, be documented in a headache diary
b Migraine headache is normally bilateral in small children; an adult pattern with unilateral pain is seen late in the adolescent period and in
young adults
c Migraine headache is typically frontotemporal. Occipital headache in children, be it unilateral or bilateral, is rare and requires diagnostic
caution, as the cause may be structural lesions
d In small children photo- and phonophobia can be deducted from how the children react
e Cyclic vomiting is an exclusion diagnosis. Medical history, physical and neurological examination should not raise suspicion of any other
condition. Thorough diagnostic assessment is always necessary to exclude any other condition. Differential diagnoses: intermittent bowel
obstruction (malrotation); kidney, liver or pancreas disease; increased intracranial pressure; poisoning; metabolic disease and epilepsy
f Medical history, and physical and neurological examinations should not provide signs of gastrointestinal or renal illness, otherwise such illness
shall be excluded through relevant assessment programmes
g Often associated with nystagmus or vomiting; unilateral throbbing headache may occur in some attacks
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The headache diary is an important diagnostic tool. Gen-
erally, the following applies:
• Older children and adolescents can keep a headache
diary with no problems.
• The majority of 7- to 11-year olds can themselves
report pain frequency and intensity, but may need an
adult to aide for the registration of other symptoms.
• In younger children, parents can observe and report
their symptoms without inﬂuencing pain results [82],
and the intensity of pain may be determined in children
by use of a visual analogue scale [83].
All children with headache should have a complete
physical and neurological examination performed. These
examinations and any other diagnostic tests are primarily
performed to exclude other causes of the child’s headache
(for further information on differential diagnoses, please
see Sects. 1, 2 and 7). The physical examination should
also include measurement of blood pressure and pulse, and
in some cases an eye examination.
10.4 Treatment
Generally, children are treated according to the same
treatment principles as adults. Migraine treatment studies
only exist for children aged 12 years or more, and gener-
ally there is no scientiﬁc evidence to support treatment of
children with other types of headache.
10.4.1 Non-pharmacological treatment
Non-pharmacological treatment should be attempted
before pharmacological treatment is initiated, but scientiﬁc
evidence is extremely limited. Generally, the following
recommendations apply (Table 22):
• Identiﬁcation and elimination/reduction of any relevant
trigger factors.
• Interview about dietary habits and sleep patterns.
• Thorough information to children as well as parents.
• Posture correction, active exercises and correct work
postures.
• Stress and pain handling, and in some cases biofeed-
back and stress relief instruction.
• Physical activity in the form of aerobics, swimming,
jogging or cycling.
10.4.2 Pharmacological treatment
Pharmacological treatment of headache conditions in chil-
dren is mainly based on studies in adults [84] (Table 23).
10.4.2.1 Acute migraine treatment There is a docu-
mented effect of treatment with weak analgesics in the
form of paracetamol or ibuprofen [85, 86] and speciﬁc
treatment with sumatriptan nasal spray [87–89] or zolmi-
triptan tablets 2.5 mg [86]. Sumatriptan nasal spray is the
only medication among the triptans which is approved for
use in children (adolescents aged 12–17 years) in Den-
mark. Controlled trials seem to indicate that ibuprofen is
superior to paracetamol [85]. Paracetamol is, however,
generally the medication which is tolerated best, and many
patients ﬁnd that the effect of the mild analgesics is com-
parable. Consequently, the choice of analgesics should be
made on the basis of effect and side effects in the patient in
question.
Generally in children aged [2 years, the effect of the
above analgesics are enhanced if supplemented by antie-
metics. Among the antiemetics, domperidone is preferred
owing to fewer extrapyramidal adverse reactions in the
form of locomotive disturbances.
Table 22 Non-pharmacological treatment of headache in children
Physical examination and reassurance
Exclude other underlying diseases, e.g. stress, psychogenic factors
(problems at home, school or/and among friends), depression,
anxiety, refraction anomalies, strabismus, eyestrain (computer
work/games), oromandibular dysfunction, sinusitis, postural
anomaly, passive/active smoking and inexpedient lifestyle
Exclude overuse of analgesics
Inform about disease mechanisms and make sure that the child and
his parents understand these
Minimise or eliminate any trigger factors, e.g. stress or
unphysiological work postures at school
Table 23 Pharmacological treatment of headache in children
The acute and prophylactic medical treatment of migraine and
tension-type headache are different
Treatment of acute attack of tension-type headache (paracetamol
and/or NSAID)
Treatment of acute migraine attack (paracetamol, and/or NSAID
combined with domperidone; alternatively sumatriptan nasal
spray)
Avoid overuse of analgesics
Prophylactic treatment is considered in very frequent or severely
incapacitating headache, where the effect of non-
pharmacological treatment has proven insufﬁcient and where
acute attack treatment is insufﬁcient
Generally, scientiﬁc evidence to underpin the effectiveness of
prophylactic medical treatment in children with migraine and
tension-type headache is very limited
Prophylactic pharmacological treatment should be given in
adequate doses for a minimum of 3 months before any decisions
can be made with regard to its effect
Treatment discontinuation should be attempted after 6–12 months
to ensure that daily medication is still necessary
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is a documented effect of paracetamol.
10.5 Prophylactic treatment
There is only indication for pharmacological prophylactic
treatment of headache in children if non-pharmacological
treatment is ineffective and/or the headache attacks are fre-
quent(morethan3–4attackspermonth),prolongedand/orso
severethattheyaffectthequalityoflifeand/orfunctionlevel.
10.5.1 Migraine prophylaxis
Beta-blockers and ﬂunarizine have a documented prophy-
lactic effect in children and adolescents [87–89], while the
evidenceforotherformsofprophylaxisissparse[87,88].Ifit
is clearly necessary to attempt other prophylactic treatments,
the following may be used in the stated order: amitriptyline,
topiramate and valproate [87, 88]. Pizotifen and clonidine, in
contrast, have no documented effect in children [88].
10.5.2 Prophylaxis of chronic tension-type headache
Prophylactic treatment with amitriptyline may possibly
have an effect on chronic tension-type headache in chil-
dren, but no placebo-controlled studies document this.
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